Posts by: Catarina Silva, MSc

Catarina Silva, MSc

With over three years of experience in the medical communications business, Catarina holds a BSc. in Biomedical Sciences and a MSc. in Neurosciences. Apart from writing, she has been involved in patient-oriented translational and clinical research.

February 18, 2020February 18, 2020

Stroke-like Symptoms May Indicate CMTX1, Case Series Suggests

News

Stroke-like symptoms and mild cognitive impairment are among non-specific symptoms that may suggest X-linked Charcot-Marie-Tooth type 1 (CMTX1), a case series shows. The series, “GJB1 Mutation-A Disease Spectrum: Report of ... Read more

January 24, 2020January 24, 2020

Tendon Transfer Surgery May Minimize CMT-related Foot Drop, Study Suggests

News

Foot drop in Charcot-Marie-Tooth disease may be corrected by transferring the end part of specific leg muscles to the midfoot region, researchers report. The study, titled “Extensor Tendon Transfers ... Read more

December 17, 2019December 17, 2019

Intermediate CMT Rates are Higher in Southeast China, with Later Onset for Type 1A, Study Suggests

News

Charcot-Marie-Tooth disease (CMT) patients from southeast China have higher rates of intermediate CMT, and patients with CMT type 1A seem to have later age of onset, when compared with ... Read more

November 6, 2019November 6, 2019

Gene Therapy Strategy Treats Charcot-Marie-Tooth Type 2D Mice, Study Shows

News

Researchers have successfully used adeno-associated virus-mediated gene therapy to treat mice that replicated a novel mutation found in a Charcot-Marie-Tooth Type 2D patient with severe disease. The study describing ... Read more

March 12, 2019March 12, 2019

Observational Trial Recruiting Participants to Identify New CMT-related Mutations

News

A research project that is now underway and recruiting participants is intended to identify new disease-causing genetic mutations in Charcot-Marie-Tooth (CMT) disease patients. The goal of the observational trial (NCT01193088), ... Read more

October 12, 2018October 12, 2018

Sarepta Acquires Rights to CMT Gene Therapy Program from Nationwide Children’s Hospital

News

Nationwide Children’s Hospital (NCH) has granted the exclusive rights of neutotrophin 3 (NT-3), its gene therapy candidate for the treatment of Charcot-Marie-Tooth (CMT) neuropathies, to Sarepta Therapeutics. Researchers plan ... Read more

Pin It on Pinterest